Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT06613750
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 129 participants
- Registry
-
NCT06613750
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06613750. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (actual); primary completion 2024-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
- Acronym
- SG Metformin
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Glucotoxicity
- Intervention (Drug)
- Sitagliptin and Gliclazide
- Intervention (Drug)
- Metformin
- Lead sponsor
- Zhibin Xu
- Collaborator
- Nanfang Hospital, Southern Medical University
Record details
- Record id
cardio:ct-nct06613750- Content hash
da37182768f8c1cd133228e1daa05984c1bf2e4b7913164fad6d22a04a9d2c0a